A Novel DNA Aptamer Probe Recognizing Castration Resistant Prostate Cancer in vitro and in vivo Based on Cell-SELEX

References

• Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. doi:10.3322/caac.21763
   PubMed Web of Science ®Google Scholar
• Hassanipour S, Delam H, Arab-Zozani M, et al. Survival rate of prostate cancer in Asian countries: a systematic review and meta-analysis. Ann Glob Health. 2020;86(1):2. doi:10.5334/aogh.2607
   PubMed Web of Science ®Google Scholar
• Desai K, McManus JM, Sharifi N. Hormonal therapy for prostate cancer. Endocr Rev. 2021;42(3):354–373. doi:10.1210/endrev/bnab002
   PubMed Web of Science ®Google Scholar
• Schaeffer E, Srinivas S, Antonarakis ES, et al. NCCN guidelines insights: prostate cancer, Version 1.2021. J Natl Compr Canc Netw. 2021;19(2):134–143. doi:10.6004/jnccn.2021.0008
   PubMed Web of Science ®Google Scholar
• Achard V, Putora PM, Omlin A, Zilli T, Fischer S. Metastatic prostate cancer: treatment options. Oncology. 2022;100(1):48–59. doi:10.1159/000519861
   PubMed Web of Science ®Google Scholar
• Varisli L, Tolan V, Cen JH, Vlahopoulos S, Cen O. Dissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: a molecular perspective. Oncol Res. 2022;30(3):137–155. doi:10.32604/or.2022.026074
   PubMed Web of Science ®Google Scholar
• Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630–642. doi:10.1016/j.eururo.2016.08.002
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.026
   PubMed Web of Science ®Google Scholar
• Cheng Q, Butler W, Zhou Y, et al. Pre-existing castration-resistant prostate cancer-like cells in primary prostate cancer promote resistance to hormonal therapy. Eur Urol. 2022;81(5):446–455. doi:10.1016/j.eururo.2021.12.039
   PubMed Web of Science ®Google Scholar
• Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 1990;249(4968):505–510. doi:10.1126/science.2200121
   PubMed Web of Science ®Google Scholar
• Darmostuk M, Rimpelova S, Gbelcova H, Ruml T. Current approaches in SELEX: an update to aptamer selection technology. Biotechnol Adv. 2015;33(6 Pt 2):1141–1161. doi:10.1016/j.biotechadv.2015.02.008
   PubMed Web of Science ®Google Scholar
• Mayer G. The chemical biology of aptamers. Angew Chem Int Ed Engl. 2009;48(15):2672–2689. doi:10.1002/anie.200804643
   PubMed Web of Science ®Google Scholar
• Cho EJ, Lee JW, Ellington AD. Applications of aptamers as sensors. Annu Rev Anal Chem. 2009;2(1):241–264. doi:10.1146/annurev.anchem.1.031207.112851
   PubMedGoogle Scholar
• Xing H, Wong NY, Xiang Y, Lu Y. DNA aptamer functionalized nanomaterials for intracellular analysis, cancer cell imaging and drug delivery. Curr Opin Chem Biol. 2012;16(3–4):429–435. doi:10.1016/j.cbpa.2012.03.016
   PubMed Web of Science ®Google Scholar
• Song KM, Lee S, Ban C. Aptamers and their biological applications. Sensors. 2012;12(1):612–631. doi:10.3390/s120100612
   PubMed Web of Science ®Google Scholar
• Iliuk AB, Hu L, Tao WA. Aptamer in bioanalytical applications. Anal Chem. 2011;83(12):4440–4452. doi:10.1021/ac201057w
   PubMed Web of Science ®Google Scholar
• Yuan B, Zhou Y, Guo Q, et al. A signal-on split aptasensor for highly sensitive and specific detection of tumor cells based on FRET. Chem Commun. 2016;52(8):1590–1593. doi:10.1039/C5CC08060F
   PubMed Web of Science ®Google Scholar
• Tan Y, Guo Q, Xie Q, et al. Single-walled carbon nanotubes (SWCNTs)-assisted cell-systematic evolution of ligands by exponential enrichment (cell-SELEX) for improving screening efficiency. Anal Chem. 2014;86(19):9466–9472. doi:10.1021/ac502166b
   PubMed Web of Science ®Google Scholar
• Zhong J, Ding J, Deng L, et al. Selection of DNA aptamers recognizing EpCAM-positive prostate cancer by cell-SELEX for in vitro and in vivo MR Imaging. Drug Des Devel Ther. 2021;15:3985–3996. doi:10.2147/DDDT.S322854
   PubMed Web of Science ®Google Scholar
• Morote J, Aguilar A, Planas J, Trilla E. Definition of castrate resistant prostate cancer: new insights. Biomedicines. 2022;10(3):689. doi:10.3390/biomedicines10030689
   PubMed Web of Science ®Google Scholar
• Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180–1192. doi:10.1111/j.1742-1241.2011.02799.x
   PubMed Web of Science ®Google Scholar
• Wang T, Chen C, Larcher LM, Barrero RA, Veedu RN. Three decades of nucleic acid aptamer technologies: lessons learned, progress and opportunities on aptamer development. Biotechnol Adv. 2019;37(1):28–50. doi:10.1016/j.biotechadv.2018.11.001
   PubMed Web of Science ®Google Scholar
• Guan B, Zhang X. Aptamers as versatile ligands for biomedical and pharmaceutical applications. Int J Nanomed. 2020;15:1059–1071. doi:10.2147/IJN.S237544
   PubMed Web of Science ®Google Scholar
• Kumar KP, Hussain B, Yuce M. Current perspectives on aptamers as diagnostic tools and therapeutic agents. Pharmaceutics. 2020;12(7):646.
   PubMed Web of Science ®Google Scholar
• Sakamoto T, Ennifar E, Nakamura Y. Thermodynamic study of aptamers binding to their target proteins. Biochimie. 2018;145:91–97. doi:10.1016/j.biochi.2017.10.010
   PubMed Web of Science ®Google Scholar
• Wei X, Xu J, Zhong S, et al. Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer. Abdom Radiol. 2022;47(10):3574–3582. doi:10.1007/s00261-022-03592-4
   PubMed Web of Science ®Google Scholar
• Fernandes MC, Yildirim O, Woo S, Vargas HA, Hricak H. The role of MRI in prostate cancer: current and future directions. MAGMA. 2022;35(4):503–521. doi:10.1007/s10334-022-01006-6
   PubMedGoogle Scholar
• Verma S, Turkbey B, Muradyan N, et al. Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management. AJR Am J Roentgenol. 2012;198(6):1277–1288. doi:10.2214/AJR.12.8510
   PubMed Web of Science ®Google Scholar
• Chelluri LK, Mohanram Y, Jain R, et al. Effect of engineered superparamagnetic iron oxide nanoparticles in targeted cardiac precursor cell delivery by MRI. Biochem Biophys Res Commun. 2021;541:15–21. doi:10.1016/j.bbrc.2021.01.005
   PubMed Web of Science ®Google Scholar
• Iacobazzi RM, Vischio F, Arduino I, et al. Magnetic implants in vivo guiding sorafenib liver delivery by superparamagnetic solid lipid nanoparticles. J Colloid Interface Sci. 2022;608(Pt 1):239–254. doi:10.1016/j.jcis.2021.09.174
   PubMedGoogle Scholar